title: Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?
authors.affiliation: Bichat-Claude Bernard University Hospital, Paris, France gerard.zalcman@aphp.fr.
authors.forename: Gérard
authors.initials: G
authors.lastname: Zalcman
authors.affiliation: Bichat-Claude Bernard University Hospital, Paris, France.
authors.forename: Solenn
authors.initials: S
authors.lastname: Brosseau
authors.affiliation: Bichat-Claude Bernard University Hospital, Paris, France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Gounant
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D066246:ErbB Receptors; D005076:Exanthema / Q000139:chemically induced*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors